We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Primary pulmonary leiomyosarcoma: A population-based study.
OBJECTIVES: Primary pulmonary leiomyosarcoma (PPL) is a rare diagnosis with poorly understood clinicopathological characteristics and disease progression. What we know is derived from limited case reports, so identification of features associated with patient survival is warranted.
MATERIALS AND METHODS: A population cohort study was conducted using prospectively extracted data from the Surveillance, Epidemiology and End Results (SEER) database for patients with histological diagnoses of PPL from 1973 to 2013 including demographic, treatment and outcome data.
RESULTS: A total of 231 patients with PPL were included (mean 65.8 ± 14.9 years-of-age). 43 were categorized with a regional stage, and 60 had localized stage, whereas 70 had distant stage. Most (60.4%) patients received cancer-directed surgery, and radiotherapy was performed for 14.1% of patients. Median overall survival (OS) was 14.0 months, and 1-, 3- and 5-year OS for PPL patients was 52.7%, 29.0% and 22.2%, respectively. Cancer-directed surgery significantly improved median OS for patients with PPL by almost 29.0 months (33.0 vs 4.0 months; p < .01). Multivariate Cox analysis showed that distant stage was independent prognostic factors for PPL (HR = 2.22, 95% CI 1.30-3.79). Conversely, cancer-directed surgery was an independent protective factor and this decreased risk of death by 57% (HR = 0.43, 95% CI 0.27-0.67) for patients with PPL.
CONCLUSION: PPL is a rare pathological lung cancer, surgical resection and distant stage were associated with prognosis. In order to understand PPL more thoroughly, more cases with adequate information are required.
MATERIALS AND METHODS: A population cohort study was conducted using prospectively extracted data from the Surveillance, Epidemiology and End Results (SEER) database for patients with histological diagnoses of PPL from 1973 to 2013 including demographic, treatment and outcome data.
RESULTS: A total of 231 patients with PPL were included (mean 65.8 ± 14.9 years-of-age). 43 were categorized with a regional stage, and 60 had localized stage, whereas 70 had distant stage. Most (60.4%) patients received cancer-directed surgery, and radiotherapy was performed for 14.1% of patients. Median overall survival (OS) was 14.0 months, and 1-, 3- and 5-year OS for PPL patients was 52.7%, 29.0% and 22.2%, respectively. Cancer-directed surgery significantly improved median OS for patients with PPL by almost 29.0 months (33.0 vs 4.0 months; p < .01). Multivariate Cox analysis showed that distant stage was independent prognostic factors for PPL (HR = 2.22, 95% CI 1.30-3.79). Conversely, cancer-directed surgery was an independent protective factor and this decreased risk of death by 57% (HR = 0.43, 95% CI 0.27-0.67) for patients with PPL.
CONCLUSION: PPL is a rare pathological lung cancer, surgical resection and distant stage were associated with prognosis. In order to understand PPL more thoroughly, more cases with adequate information are required.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app